StockNews.com started coverage on shares of Tenax Therapeutics (NASDAQ:TENX – Free Report) in a report issued on Monday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Tenax Therapeutics Price Performance
Shares of NASDAQ:TENX opened at $3.82 on Monday. The business’s 50 day simple moving average is $3.59 and its 200 day simple moving average is $3.68. Tenax Therapeutics has a 1 year low of $2.77 and a 1 year high of $61.20.
Tenax Therapeutics (NASDAQ:TENX – Get Free Report) last released its earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.99) by $0.16. On average, equities analysts predict that Tenax Therapeutics will post -6.68 EPS for the current year.
Tenax Therapeutics Company Profile
Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Featured Articles
- Five stocks we like better than Tenax Therapeutics
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Why Dick’s Could Be a Slam Dunk for Your Investment Portfolio
- What are earnings reports?
- Introduction to Fibonacci Retracement Levels
- The How And Why of Investing in Oil Stocks
- Top 3 Stocks to Outperform the S&P 500 in a Downturn
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
